Shares of Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) have earned a consensus rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $22.50.
Several brokerages have weighed in on DCTH. Zacks Research cut shares of Delcath Systems from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th.
Delcath Systems Price Performance
Delcath Systems (NASDAQ:DCTH – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.07. The firm had revenue of $24.99 million for the quarter, compared to analysts’ expectations of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. As a group, equities analysts expect that Delcath Systems will post -0.88 EPS for the current fiscal year.
Institutional Trading of Delcath Systems
A number of hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in Delcath Systems during the second quarter valued at approximately $26,000. Russell Investments Group Ltd. bought a new stake in Delcath Systems in the third quarter worth $29,000. Tower Research Capital LLC TRC bought a new stake in Delcath Systems in the second quarter worth $40,000. Legal & General Group Plc purchased a new position in Delcath Systems during the second quarter worth $46,000. Finally, The Manufacturers Life Insurance Company bought a new position in Delcath Systems during the second quarter valued at $151,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.
Delcath Systems Company Profile
Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.
Featured Articles
- Five stocks we like better than Delcath Systems
- 2 AI Stocks That Could Benefit as AI Moves Beyond the Data Center
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
